Clinical Trial Update: Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting safety and the impact on humoral sensitization of SANGUINATE in patients with end-stage renal disease due to chronic renal insuff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Renal Insufficiency, Chronic | Phase 1 | Status: COMPLETED